Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
5.26%
1 month
11.11%
YTD
-23.08%
1 year
-27.27%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Industrials
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
04 October 24 |
Change in Canadian status to Designated Foreign Issuer
×
Change in Canadian status to Designated Foreign Issuer |
03 October 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
30 September 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 September 24 |
Preliminary Final Report Reporting Adjustments
×
Preliminary Final Report Reporting Adjustments |
30 September 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 24 |
2024 AGM Notice of Meeting, Letter of Access and Proxy
×
2024 AGM Notice of Meeting, Letter of Access and Proxy |
23 September 24 |
Director transition
×
Director transition |
06 September 24 |
2024 Annual General Meeting
×
2024 Annual General Meeting |
02 September 24 |
Appointment of Chief Financial Officer
×
Appointment of Chief Financial Officer |
30 August 24 |
Appendix 4E Preliminary Final Report
×
Appendix 4E Preliminary Final Report |
26 August 24 |
Completion of patient dosing in maiden TRP-8803 trial
×
Completion of patient dosing in maiden TRP-8803 trial |
12 August 24 |
Positive Phase 2a fibromyalgia results across all patients
×
Positive Phase 2a fibromyalgia results across all patients |
07 August 24 |
Trading Halt
×
Trading Halt |
31 July 24 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
30 July 24 |
Appointment of Professor Phillipa Hay to TYPs SAB
×
Appointment of Professor Phillipa Hay to TYPs SAB |
30 July 24 |
TechKnow Invest Roadshow presentation and livestream links
×
TechKnow Invest Roadshow presentation and livestream links |
29 July 24 |
Psychiatry professor David Castle appointed to TYPs SAB
×
Psychiatry professor David Castle appointed to TYPs SAB |
24 July 24 |
First patient dosed in Phase 2a IBS trial at Mass General
×
First patient dosed in Phase 2a IBS trial at Mass General |
22 July 24 |
Notification of cessation of securities - TYP
×
Notification of cessation of securities - TYP |
10 July 24 |
Phase 2a Fibromyalgia clinical study completed at U-M
×
Phase 2a Fibromyalgia clinical study completed at U-M |
01 July 24 |
Maiden dosing of TRP-8803 completed in global first
×
Maiden dosing of TRP-8803 completed in global first |
26 June 24 |
Dr Robin Carhart-Harris renews role as SAB Chair
×
Dr Robin Carhart-Harris renews role as SAB Chair |
19 June 24 |
Appointment product registration & reimbursement strategy
×
Appointment product registration & reimbursement strategy |
17 June 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
07 June 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.